Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (1)
P 2 (2)
P 3 (1)

Trial Status

Recruiting4
Not Yet Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07754682Phase 3Not Yet Recruiting

Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma

NCT06764238Phase 2Recruiting

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

NCT05480449Phase 1RecruitingPrimary

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

NCT06882057Phase 2Recruiting

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

NCT06785324Not ApplicableRecruiting

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Showing all 5 trials

Research Network

Activity Timeline